Department of Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt
Research Article
Effect of Vildagliptin versus Vildagliptin plus Metformin on Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus
Author(s): Aya Gamal Moussa*, Gamal Abdelkhalek Alazab, Osama Mohamed Ibrahim and Yasser Mohamed Abdelraouf
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is believed to be the most common chronic liver disease. The present study aimed to evaluate the efficacy of the vildagliptin versus vildagliptin / metformin combination in the treatment of nonalcoholic fatty liver disease patients with type 2 diabetes mellitus (T 2DM).
Methods: One hundred twenty patients, who were newly diagnosed with T 2DM, and proof of diagnosis of NAFLD, were enrolled in a twelve-month open label prospective parallel study. The patients were divided into two groups; Group 1 received vildagliptin in a dose of 50 mg twice daily and Group 2 received vildagliptin/metformin in a dose of 50 mg/ 1000 mg twice daily. Body mass index and fatty liver ultrasound grading were evaluated with the assay of HbA1c and serum levels of fasting and postprandial glucose, lipid profile,.. View More»
DOI:
10.35248/2155-6156.21.12.890
